. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Diabetologia. 2018 Dec 19;62(4):655–664. doi: 10.1007/s00125-018-4786-9

Table 1.

Characteristics of participants who returned, at study enrolment

Characteristic	Control group (n=12)	Teplizumab group (n=31)	p value
Age at enrolment (years)	12.27±0.86	11.94±0.57	0.76
Duration of diabetes at enrolment (days)	37.33±2.86	39.55±1.47	0.46
Male sex (%)	66.7	58.1	0.27
White (%)	100	87.1	0.19
Minority^a (%)	0	9.7	0.26
BMI (kg/m²)	19.6±0.78	18.91±0.61	0.53
Insulin use (U kg⁻¹ day⁻¹)	0.40±0.04	0.35±0.05	0.66
HbA_1c (mmol/mol)	60.15±4.56	57.58±2.04	0.56
HbA_1c (%)	7.66±0.42	7.42±0.19	0.56
C-peptide AUC^b (nmol/l)	0.50±0.05	0.52±0.03	0.81
Data are mean ± SEM.

Ethnic minority, including African-American and Native American participants in this study

log_e [(AUC/240)+1], presented in nmol/l